Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCD in Relapsed/Refractory Multiple Myeloma
NCT03242460Phase 2Completed
- Start
- May 2015
- Primary completion
- Apr 2019
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in multiple myeloma (MM). Primary endpoint: Progression-Free Survival at 2 years. Started May 2015; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03242460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03242460.